Pillar Biosciences Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 46
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 4

Pillar Biosciences General Information

Description

Developer of targeted next-generation sequencing (NGS)-based software intended to streamline mapping and on-target metrics. The company's platform offers an economical workflow with high mapping and on-target metrics technology for cell-free DNA in order to develop medical research accessible through a cost-effective sequencing combined with bioinformatics analyses, enabling the healthcare industry to simplify DNA analysis functions in an efficient manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Biotechnology
Primary Office
  • 9 Strathmore Road
  • Natick, MA 01760
  • United States
+1 (800) 000-0000

Pillar Biosciences Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pillar Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Debt - PPP 02-May-2020 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 10-Mar-2020 000.00 000.00 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 01-Nov-2018 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A2) 11-May-2016 $18M $20.8M 000.00 Completed Product In Beta Test
1. Angel (individual) $2.8M $2.8M 0000 Completed Product In Beta Test
To view Pillar Biosciences’s complete valuation and funding history, request access »

Pillar Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A2 6,853,820 $0.000100 8% $2.63 $2.63 1x $2.63 15.88%
Series A1 5,466,965 $0.000100 8% $0.53 $0.53 1x $0.53 12.67%
To view Pillar Biosciences’s complete cap table history, request access »

Pillar Biosciences Executive Team (6)

Name Title Board Seat Contact Info
Gang Song Ph.D Co-Founder, Chief Executive Officer and Board Member
Martin Zillmann Ph.D Chief Operating Officer
Zhaohui Wang Ph.D Co-Founder & Chief Science Officer
Manfred Scholz Ph.D Chief Commercial Officer
Cheng-Zhong Zhang Ph.D Co-Founder and Scientific Advisory Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Pillar Biosciences Board Members (5)

Name Representing Role Since
Cheng-Zhong Zhang Ph.D Pillar Biosciences Co-Founder and Scientific Advisory Board Member 000 0000
Gang Song Ph.D Pillar Biosciences Co-Founder, Chief Executive Officer and Board Member 000 0000
Hong Fang Sang Pillar Biosciences Board Member 000 0000
Hui Yang Pillar Biosciences Board Member 000 0000
Shawn Liu Pillar Biosciences Board Member 000 0000
To view Pillar Biosciences’s complete board members history, request access »

Pillar Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pillar Biosciences Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
China Biotech Services Holdings Corporation Minority 000 0000 000000 0
Oriental Fortune Capital Venture Capital Minority 000 0000 000000 0
ORI Capital Venture Capital Minority 000 0000 000000 0
ZhenFund Venture Capital Minority 000 0000 000000 0
To view Pillar Biosciences’s complete investors history, request access »